Related Experiment Video
Updated: Aug 1, 2026
06:38
Early Detection of Drug-Induced Renal Hemodynamic Dysfunction Using Sonographic Technology in Rats
Published on: March 11, 2016
[Transition of renal function after repeated intraperitoneal CDDP administration]
K Arai1, M Kitamura, Y Iwasaki
1Dept. of Surgery, Tokyo Metropolitan Komagome Hospital.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|September 1, 1996
Summary
Intraperitoneal cisplatin (CDDP) after gastrectomy frequently caused renal dysfunction in outpatients. Current methods cannot easily or sensitively detect these kidney function changes, making the treatment not recommended.
Area of Science:
- Oncology
- Nephrology
- Gastroenterology
Context:
- Post-gastrectomy cancer treatment
- Intraperitoneal chemotherapy administration
- Management of advanced gastric cancer
Purpose:
- To evaluate the incidence and severity of renal dysfunction following intraperitoneal cisplatin (CDDP) administration in patients post-gastrectomy.
- To assess the tolerability of this treatment regimen for outpatient settings.
- To identify potential indicators of renal impairment during CDDP chemotherapy.
Summary:
- This study monitored 20 patients receiving intraperitoneal CDDP post-gastrectomy, with doses ranging from 90-400 mg.
- Renal dysfunction (up to grade 2) occurred in 35% of patients, and 12% of all administrations showed adverse renal events.
- Creatinine clearance declined with cumulative CDDP dose, but serum creatinine and BUN levels did not correlate, indicating a lack of sensitive biomarkers.
Impact:
- Highlights the significant risk of renal dysfunction with intraperitoneal CDDP in post-gastrectomy patients.
- Suggests that current clinical markers are insufficient for early detection of CDDP-induced nephrotoxicity in this setting.
- Discourages the use of intraperitoneal CDDP for outpatients due to safety concerns and monitoring limitations.
Related Concept Videos
01:25Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
01:26Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Continuous Renal Replacement Therapy (CRRT) is an essential intervention for patients experiencing severe kidney dysfunction. This therapy offers a continuous mechanism for removing fluids and toxins from the bloodstream, leveraging the patient’s blood pressure to facilitate filtration through a specialized filter. This method contrasts with intermittent dialysis, providing a gentler and more consistent removal of waste products and excess fluid, which is particularly beneficial in critically...
01:25Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications
Peritoneal dialysis (PD) is a medical process that removes waste products and excess fluid from the body using the peritoneal membrane as a natural filter.Peritoneal Dialysis MethodsSeveral methods can be used for peritoneal dialysis, including Acute Intermittent Peritoneal Dialysis, Continuous Ambulatory Peritoneal Dialysis, and Automated Peritoneal Dialysis, also known as Continuous Cyclic Peritoneal Dialysis.Acute Intermittent Peritoneal Dialysis (AIPD) is used for patients with uremic...
01:30Continuous Renal Replacement Therapy
Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
01:26Kidney Transplant II: Surgical Procedure
Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living donor...
01:29Acute Kidney Injury III: Clinical Manifestations
Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...